No Data
No Data
Piper Sandler Maintains Altimmune(ALT.US) With Buy Rating, Maintains Target Price $25
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT), Altimmune (ALT) and Steris (STE)
Lilly Looking to Test Zepbound as Health Maintenance Drug: Report
Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference
Roche Sees Carmot Obesity Drugs' Potential Peak Sales at $3.6B+: Report
Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis